9 minutes ago
For World COPD Day, Vickram Tejwani, MD, says single exacerbations warrant urgency and calls out gaps in spirometry use and initial COPD therapy.
5 hours ago
Sparsentan, B cell therapies, and TRPC6 and APOL1 inhibitors may each fit a different stage and cause of FSGS.
6 hours ago
A renal pathologist explains how biopsy findings, clinical context, anti-nephrin antibodies and genetics shape FSGS workup.
6 hours ago
In this Q&A, Jennifer K. Priessnitz, MD, explains why FAERS reporting proportions should not drive biologic selection and what data are needed next.
8 hours ago
At ACAAI 2026, Jennifer Priessnitz, MD presented data which found omalizumab had the highest anaphylaxis reporting proportion among 7 respiratory biologics.